{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:15:48Z","timestamp":1791983748978,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Competitive allocation project of special funds for science and technology development in Zhanjiang City","award":["2022A01200"],"award-info":[{"award-number":["2022A01200"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Genom Data"],"DOI":"10.1186\/s12863-024-01292-0","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T08:58:50Z","timestamp":1736499530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ERBB3-related gene PBX1 is associated with prognosis in patients with HER2-positive breast cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Shufen","family":"Mo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taidong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1517-1327","authenticated-orcid":false,"given":"Yongguang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"1292_CR1","doi-asserted-by":"publisher","unstructured":"Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics. 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","DOI":"10.3322\/caac.21660"},{"issue":"10087","key":"1292_CR2","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1016\/s0140-6736(16)32417-5","volume":"389","author":"S Loibl","year":"2017","unstructured":"Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389(10087):2415\u20132429. https:\/\/doi.org\/10.1016\/s0140-6736(16)32417-5.","journal-title":"Lancet"},{"issue":"2","key":"1292_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, et al. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19(2):91\u2013113. https:\/\/doi.org\/10.1038\/s41571-021-00565-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"1292_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"DY Oh","year":"2020","unstructured":"Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33\u201348. https:\/\/doi.org\/10.1038\/s41571-019-0268-3.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"1292_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E. Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov. 2023;22(2):101\u2013126. https:\/\/doi.org\/10.1038\/s41573-022-00579-0.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1292_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41568-020-00322-0","volume":"21","author":"S Kumagai","year":"2021","unstructured":"Kumagai S, Koyama S, Nishikawa H. Antitumour immunity regulated by aberrant ERBB family signalling. Nat Rev Cancer. 2021;21(3):181\u2013197. https:\/\/doi.org\/10.1038\/s41568-020-00322-0.","journal-title":"Nat Rev Cancer"},{"key":"1292_CR7","doi-asserted-by":"publisher","first-page":"102436","DOI":"10.1016\/j.ctrv.2022.102436","volume":"109","author":"JZ Drago","year":"2022","unstructured":"Drago JZ, Ferraro E, Abuhadra N, et al. Beyond HER2: targeting the ErbB receptor family in breast cancer. Cancer Treat Rev. 2022;109:102436. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102436.","journal-title":"Cancer Treat Rev"},{"key":"1292_CR8","doi-asserted-by":"publisher","unstructured":"Kemmer S, Berdiel-Acer M, Reinz E, et al. Disentangling ERBB signaling in breast Cancer Subtypes-A model-based analysis. Cancers (Basel). 2022;14(10). https:\/\/doi.org\/10.3390\/cancers14102379.","DOI":"10.3390\/cancers14102379"},{"issue":"7888","key":"1292_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41586-021-04084-z","volume":"600","author":"D Diwanji","year":"2021","unstructured":"Diwanji D, Trenker R, Thaker TM, Wang F, Agard DA, Verba KA, et al. Structures of the HER2-HER3-NRG1\u03b2 complex reveal a dynamic dimer interface. Nature. 2021;600(7888):339\u2013343. https:\/\/doi.org\/10.1038\/s41586-021-04084-z.","journal-title":"Nature"},{"issue":"Pt 2","key":"1292_CR10","doi-asserted-by":"publisher","first-page":"124765","DOI":"10.1016\/j.ijbiomac.2023.124765","volume":"242","author":"P Dey","year":"2023","unstructured":"Dey P, Gadewal N, De A. Pathogenic HER3 dimerization domain mutations create a structural bias towards un-conventional EGFR-HER3 signalling axis in breast cancer. Int J Biol Macromol. 2023;242(Pt 2):124765. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.124765.","journal-title":"Int J Biol Macromol"},{"issue":"8","key":"1292_CR11","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.ccell.2021.06.001","volume":"39","author":"AB Hanker","year":"2021","unstructured":"Hanker AB, Brown BP, Meiler J, et al. Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2\/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. Cancer Cell. 2021;39(8):1099\u2013e11141098. https:\/\/doi.org\/10.1016\/j.ccell.2021.06.001.","journal-title":"Cancer Cell"},{"issue":"1","key":"1292_CR12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12967-021-02842-1","volume":"19","author":"MJ Mezynski","year":"2021","unstructured":"Mezynski MJ, Farrelly AM, Cremona M, et al. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer. J Transl Med. 2021;19(1):184. https:\/\/doi.org\/10.1186\/s12967-021-02842-1.","journal-title":"J Transl Med"},{"issue":"4","key":"1292_CR13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ccr.2011.10.006","volume":"20","author":"G Vlacich","year":"2011","unstructured":"Vlacich G, Coffey RJ. Resistance to EGFR-targeted therapy: a family affair. Cancer Cell. 2011;20(4):423\u2013425. https:\/\/doi.org\/10.1016\/j.ccr.2011.10.006.","journal-title":"Cancer Cell"},{"issue":"10","key":"1292_CR14","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1158\/0008-5472.Can-11-3594","volume":"72","author":"DB Vaught","year":"2012","unstructured":"Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, Rinehart C, et al. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res. 2012;72(10):2672\u20132682. https:\/\/doi.org\/10.1158\/0008-5472.Can-11-3594.","journal-title":"Cancer Res"},{"issue":"7","key":"1292_CR15","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. https:\/\/doi.org\/10.1093\/nar\/gkv007.","journal-title":"Nucleic Acids Res"},{"issue":"15","key":"1292_CR16","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1093\/bioinformatics\/btac409","volume":"38","author":"EK Gustavsson","year":"2022","unstructured":"Gustavsson EK, Zhang D, Reynolds RH, Garcia-Ruiz S, Ryten M. Ggtranscript: an R package for the visualization and interpretation of transcript isoforms using ggplot2. Bioinformatics. 2022;38(15):3844\u20133846. https:\/\/doi.org\/10.1093\/bioinformatics\/btac409.","journal-title":"Bioinformatics"},{"issue":"D1","key":"1292_CR17","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587\u2013592. https:\/\/doi.org\/10.1093\/nar\/gkac963.","journal-title":"Nucleic Acids Res"},{"issue":"43","key":"1292_CR18","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545\u201315550. https:\/\/doi.org\/10.1073\/pnas.0506580102.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1292_CR19","doi-asserted-by":"publisher","first-page":"1019638","DOI":"10.3389\/fimmu.2022.1019638","volume":"13","author":"Q Wang","year":"2022","unstructured":"Wang Q, Qiao W, Zhang H, et al. Nomogram established on account of Lasso-Cox regression for predicting recurrence in patients with early-stage hepatocellular carcinoma. Front Immunol. 2022;13:1019638. https:\/\/doi.org\/10.3389\/fimmu.2022.1019638.","journal-title":"Front Immunol"},{"key":"1292_CR20","doi-asserted-by":"publisher","first-page":"103690","DOI":"10.1016\/j.jbi.2021.103690","volume":"115","author":"S Asadi","year":"2021","unstructured":"Asadi S, Roshan S, Kattan MW. Random forest swarm optimization-based for heart diseases diagnosis. J Biomed Inf. 2021;115:103690. https:\/\/doi.org\/10.1016\/j.jbi.2021.103690.","journal-title":"J Biomed Inf"},{"key":"1292_CR21","doi-asserted-by":"publisher","first-page":"e46891","DOI":"10.2196\/46891","volume":"25","author":"G Huang","year":"2023","unstructured":"Huang G, Jin Q, Mao Y. Predicting the 5-Year risk of nonalcoholic fatty liver Disease using machine learning models: prospective cohort study. J Med Internet Res. 2023;25:e46891. https:\/\/doi.org\/10.2196\/46891.","journal-title":"J Med Internet Res"},{"key":"1292_CR22","doi-asserted-by":"publisher","unstructured":"Guan M, Jiao Y, Zhou L. Immune Infiltration Analysis with the CIBERSORT Method in Lung Cancer. Dis Markers. 2022;2022(3186427). https:\/\/doi.org\/10.1155\/2022\/3186427.","DOI":"10.1155\/2022\/3186427"},{"key":"1292_CR23","doi-asserted-by":"publisher","first-page":"1046410","DOI":"10.3389\/fimmu.2022.1046410","volume":"13","author":"Y Lai","year":"2022","unstructured":"Lai Y, Lin P, Lin F, et al. Identification of immune microenvironment subtypes and signature genes for Alzheimer\u2019s disease diagnosis and risk prediction based on explainable machine learning. Front Immunol. 2022;13:1046410. https:\/\/doi.org\/10.3389\/fimmu.2022.1046410.","journal-title":"Front Immunol"},{"issue":"26","key":"1292_CR24","doi-asserted-by":"publisher","first-page":"11938","DOI":"10.7150\/thno.49451","volume":"10","author":"S Sui","year":"2020","unstructured":"Sui S, An X, Xu C, Li Z, Hua Y, Huang G, et al. An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer. Theranostics. 2020;10(26):11938\u201311949. https:\/\/doi.org\/10.7150\/thno.49451.","journal-title":"Theranostics"},{"issue":"2","key":"1292_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","volume":"5","author":"Y Feng","year":"2018","unstructured":"Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77\u2013106. https:\/\/doi.org\/10.1016\/j.gendis.2018.05.001.","journal-title":"Genes Dis"},{"issue":"11","key":"1292_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.trecan.2017.09.001","volume":"3","author":"SK Yeo","year":"2017","unstructured":"Yeo SK, Guan JL. Breast Cancer: multiple subtypes within a Tumor? Trends Cancer. 2017;3(11):753\u2013760. https:\/\/doi.org\/10.1016\/j.trecan.2017.09.001.","journal-title":"Trends Cancer"},{"key":"1292_CR27","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.breast.2016.07.009","volume":"29","author":"MJ Duffy","year":"2016","unstructured":"Duffy MJ, O\u2019Donovan N, McDermott E, et al. Validated biomarkers: the key to precision treatment in patients with breast cancer. Breast. 2016;29:192\u2013201. https:\/\/doi.org\/10.1016\/j.breast.2016.07.009.","journal-title":"Breast"},{"key":"1292_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2147\/bctt.S189224","volume":"11","author":"P Dey","year":"2019","unstructured":"Dey P, Rathod M, De A. Targeting stem cells in the realm of drug-resistant breast cancer. Breast Cancer (Dove Med Press). 2019;11:115\u2013135. https:\/\/doi.org\/10.2147\/bctt.S189224.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"5","key":"1292_CR29","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s13402-022-00693-6","volume":"45","author":"P Dey","year":"2022","unstructured":"Dey P, Joshi M, Mujawar A, Malhotra R, De A. Direct knockdown of phospho-PTM targets mediated by TRIM21 can improve personalized treatment in breast cancer. Cell Oncol (Dordr). 2022;45(5):873\u2013891. https:\/\/doi.org\/10.1007\/s13402-022-00693-6.","journal-title":"Cell Oncol (Dordr)"},{"issue":"12","key":"1292_CR30","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1073\/pnas.1016140108","volume":"108","author":"JT Garrett","year":"2011","unstructured":"Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, S\u00e1nchez V, Chakrabarty A, et al. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA. 2011;108(12):5021\u20135026. https:\/\/doi.org\/10.1073\/pnas.1016140108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"1292_CR31","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1158\/0008-5472.Can-08-0380","volume":"68","author":"ST Lee-Hoeflich","year":"2008","unstructured":"Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008;68(14):5878\u20135887. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-0380.","journal-title":"Cancer Res"},{"issue":"8","key":"1292_CR32","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1073\/pnas.1018001108","volume":"109","author":"A Chakrabarty","year":"2012","unstructured":"Chakrabarty A, S\u00e1nchez V, Kuba MG, Rinehart C, Arteaga CL. Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA. 2012;109(8):2718\u20132723. https:\/\/doi.org\/10.1073\/pnas.1018001108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1292_CR33","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jss.2013.02.045","volume":"183","author":"R Hwaiz","year":"2013","unstructured":"Hwaiz R, Hasan Z, Rahman M, et al. Rac1 signaling regulates sepsis-induced pathologic inflammation in the lung via attenuation of Mac-1 expression and CXC chemokine formation. J Surg Res. 2013;183(2):798\u2013807. https:\/\/doi.org\/10.1016\/j.jss.2013.02.045.","journal-title":"J Surg Res"},{"issue":"5","key":"1292_CR34","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.it.2017.01.006","volume":"38","author":"N Amatya","year":"2017","unstructured":"Amatya N, Garg AV, Gaffen SL. IL-17 signaling: the Yin and the Yang. Trends Immunol. 2017;38(5):310\u2013322. https:\/\/doi.org\/10.1016\/j.it.2017.01.006.","journal-title":"Trends Immunol"},{"issue":"5","key":"1292_CR35","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.12.040","volume":"176","author":"C Jin","year":"2019","unstructured":"Jin C, Lagoudas GK, Zhao C, et al. Commensal microbiota promote Lung Cancer Development via \u03b3\u03b4 T cells. Cell. 2019;176(5):998\u2013e10131016. https:\/\/doi.org\/10.1016\/j.cell.2018.12.040.","journal-title":"Cell"},{"issue":"7556","key":"1292_CR36","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature14282","volume":"522","author":"SB Coffelt","year":"2015","unstructured":"Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, et al. IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522(7556):345\u2013348. https:\/\/doi.org\/10.1038\/nature14282.","journal-title":"Nature"},{"issue":"9","key":"1292_CR37","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/nm.3291","volume":"19","author":"AS Chung","year":"2013","unstructured":"Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med. 2013;19(9):1114\u20131123. https:\/\/doi.org\/10.1038\/nm.3291.","journal-title":"Nat Med"},{"issue":"1","key":"1292_CR38","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1186\/s12967-024-05445-8","volume":"22","author":"M Zhu","year":"2024","unstructured":"Zhu M, Yu M, Meng Y, et al. HER3 receptor and its role in the therapeutic management of metastatic breast cancer. J Transl Med. 2024;22(1):665. https:\/\/doi.org\/10.1186\/s12967-024-05445-8.","journal-title":"J Transl Med"},{"issue":"11","key":"1292_CR39","doi-asserted-by":"publisher","first-page":"e1002368","DOI":"10.1371\/journal.pgen.1002368","volume":"7","author":"L Magnani","year":"2011","unstructured":"Magnani L, Ballantyne EB, Zhang X, et al. PBX1 genomic pioneer function drives ER\u03b1 signaling underlying progression in breast cancer. PLoS Genet. 2011;7(11):e1002368. https:\/\/doi.org\/10.1371\/journal.pgen.1002368.","journal-title":"PLoS Genet"},{"issue":"26","key":"1292_CR40","doi-asserted-by":"publisher","first-page":"21878","DOI":"10.18632\/oncotarget.4243","volume":"6","author":"L Magnani","year":"2015","unstructured":"Magnani L, Patten DK, Nguyen VT, Hong SP, Steel JH, Patel N, et al. The pioneer factor PBX1 is a novel driver of metastatic progression in ER\u03b1-positive breast cancer. Oncotarget. 2015;6(26):21878\u201321891. https:\/\/doi.org\/10.18632\/oncotarget.4243.","journal-title":"Oncotarget"},{"issue":"1","key":"1292_CR41","doi-asserted-by":"publisher","first-page":"4484","DOI":"10.1038\/s41598-019-40826-w","volume":"9","author":"HM Hsu","year":"2019","unstructured":"Hsu HM, Chu CM, Chang YJ, et al. Six novel immunoglobulin genes as biomarkers for better prognosis in triple-negative breast cancer by gene co-expression network analysis. Sci Rep. 2019;9(1):4484. https:\/\/doi.org\/10.1038\/s41598-019-40826-w.","journal-title":"Sci Rep"},{"issue":"6","key":"1292_CR42","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/sj.bjc.6604621","volume":"99","author":"J Panse","year":"2008","unstructured":"Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Barrels K, et al. Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br J Cancer. 2008;99(6):930\u2013938. https:\/\/doi.org\/10.1038\/sj.bjc.6604621.","journal-title":"Br J Cancer"},{"issue":"3","key":"1292_CR43","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.clbc.2012.03.006","volume":"12","author":"E Razis","year":"2012","unstructured":"Razis E, Kalogeras KT, Kotoula V, Eleftheraki AG, Nikitas N, Kronenwett R, et al. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. Clin Breast Cancer. 2012;12(3):183\u2013193. https:\/\/doi.org\/10.1016\/j.clbc.2012.03.006.","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"1292_CR44","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, et al. Immunological effects of Conventional Chemotherapy and targeted Anticancer agents. Cancer Cell. 2015;28(6):690\u2013714. https:\/\/doi.org\/10.1016\/j.ccell.2015.10.012.","journal-title":"Cancer Cell"},{"key":"1292_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ircmb.2016.09.008","volume":"331","author":"L de la Cruz-Merino","year":"2017","unstructured":"de la Cruz-Merino L, Chiesa M, Caballero R, et al. Breast Cancer Immunology and Immunotherapy: current status and future perspectives. Int Rev Cell Mol Biol. 2017;331:1\u201353. https:\/\/doi.org\/10.1016\/bs.ircmb.2016.09.008.","journal-title":"Int Rev Cell Mol Biol"},{"issue":"1","key":"1292_CR46","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","volume":"19","author":"C Li","year":"2020","unstructured":"Li C, Jiang P, Wei S, et al. Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer. 2020;19(1):116. https:\/\/doi.org\/10.1186\/s12943-020-01234-1.","journal-title":"Mol Cancer"}],"container-title":["BMC Genomic Data"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12863-024-01292-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12863-024-01292-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12863-024-01292-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T08:58:55Z","timestamp":1736499535000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgenet.biomedcentral.com\/articles\/10.1186\/s12863-024-01292-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1292"],"URL":"https:\/\/doi.org\/10.1186\/s12863-024-01292-0","relation":{},"ISSN":["2730-6844"],"issn-type":[{"value":"2730-6844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors consent for the manuscript to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}